



NOTIFICATION PURSUANT TO

18 V.S.A. § 4637 (c)

Subject: Notification Pursuant to 18 V.S.A. § 4637(c)

To the Office of the Attorney General of Vermont:

On 8 April 2020, Aimmune Therapeutics, Inc. (“Aimmune”) notified the Office of the Attorney General of Vermont of a new prescription drug (Palforzia), pursuant to § 4637(b). Aimmune hereby notifies the Attorney General of Vermont of the following information, pursuant to § 4637(c):

Name of New Prescription Drug	NDC Number	Date of Commercial Availability	WAC (Wholesale Acquisition Cost) (As of the Date of Commercial Availability)
PALFORZIA Initial Dose Escalation Card -- 0.5 mg-6 mg	71881011313	3/10/2020	\$30.00
PALFORZIA Up-Dosing Pack -- 3 mg	71881010145	3/10/2020	\$445.00
PALFORZIA Up-Dosing Pack -- 6 mg	71881010290	3/10/2020	\$445.00
PALFORZIA Up-Dosing Pack -- 12 mg	71881010345	3/10/2020	\$445.00
PALFORZIA Up-Dosing Pack -- 20 mg	71881010415	3/10/2020	\$445.00
PALFORZIA Up-Dosing Pack -- 40 mg	71881010530	3/10/2020	\$445.00
PALFORZIA Up-Dosing Pack -- 80 mg	71881010660	3/10/2020	\$445.00
PALFORZIA Up-Dosing Pack -- 120 mg	71881010730	3/10/2020	\$445.00
PALFORZIA Up-Dosing Pack -- 160 mg	71881010860	3/10/2020	\$445.00
PALFORZIA Up-Dosing Pack -- 200 mg	71881010930	3/10/2020	\$445.00
PALFORZIA Up-Dosing Pack -- 240 mg	71881011060	3/10/2020	\$445.00
PALFORZIA Up-Dosing Pack -- 300 mg, 15 count sachet	71881011115	3/10/2020	\$445.00
PALFORZIA Maintenance Dosing Pack -- 300 mg, 30 count sachet	71881011130	3/10/2020	\$890.00

Description of the marketing and pricing plans used in the launch of Palforzia in the United States:

Marketing activities that support the launch of a new treatment are designed to raise awareness and understanding with healthcare providers and patients about the approved indication(s), efficacy and safety data contained within the treatment's FDA approved label.

Our pricing is intended to facilitate access for all eligible patients, support timely reimbursement and financial assistance for the commercially-insured, as well as patient assistance for eligible uninsured or under-insured patients.



Palforzia (Peanut (Arachis hypogaea) Allergen Powder-dnfp) was Breakthrough Therapy Designation in June 2015 for peanut-allergic children and adolescents ages 4-17, which was preceded by the granting of Fast Track Designation in September 2014.

The estimated volume of patients who may be prescribed Palforzia:

Aimmune does not publicly disclose the estimated volume of patients who may be prescribed Palforzia.

The date and price of acquisition if the drug was not developed by the manufacturer:

Palforzia was developed, and is promoted, by Aimmune. Palforzia was not acquired from a third party.

Sincerely,

Raymond Wang

Raymond Wang
Associate Director, Pricing and Contracting Operations
Aimmune Therapeutics, Inc.